$CAPR
CAPRICOR THERAPEUTICS, INC.

2024 Q1 Form 10-K Financial Statement

#000155837024002861 Filed on March 11, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $4.907M $12.09M $25.18M
YoY Change 64.29% 364.93% 886.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.072M $3.429M $12.81M
YoY Change 16.01% 22.72% 22.78%
% of Gross Profit
Research & Development $11.10M $9.940M $17.15M
YoY Change 44.16% 59.51% -21.31%
% of Gross Profit
Depreciation & Amortization $331.4K $307.6K $1.069M
YoY Change 44.03% 60.55% 100.49%
% of Gross Profit
Operating Expenses $15.17M $13.37M $30.59M
YoY Change 35.82% 48.12% -5.15%
Operating Profit -$10.27M -$24.08M
YoY Change 25.43% -18.92%
Interest Expense $471.8K $452.2K $1.729M
YoY Change 13.3% 19.09% 231.46%
% of Operating Profit
Other Income/Expense, Net $471.8K $67.66K $67.66K
YoY Change 13.3% -90.02%
Pretax Income -$9.794M -$762.1K -$22.29M
YoY Change 26.08% -90.13% -23.2%
Income Tax
% Of Pretax Income
Net Earnings -$9.794M -$762.1K -$22.29M
YoY Change 26.08% -90.13% -23.2%
Net Earnings / Revenue -199.6% -6.3% -88.52%
Basic Earnings Per Share -$0.31 -$0.83
Diluted Earnings Per Share -$0.31 -$0.02 -$0.83
COMMON SHARES
Basic Shares Outstanding 31.40M 30.79M 26.78M
Diluted Shares Outstanding 31.35M 26.78M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.92M $39.49M $39.49M
YoY Change -11.63% -4.67% -4.67%
Cash & Equivalents $6.215M $14.69M $14.69M
Short-Term Investments $33.70M $24.79M $24.79M
Other Short-Term Assets $1.126M $995.8K $995.8K
YoY Change 28.65% 8.25% 8.25%
Inventory
Prepaid Expenses $291.4K
Receivables $369.0K $10.37M $10.37M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $41.41M $50.86M $50.86M
YoY Change -11.12% 18.58% 18.58%
LONG-TERM ASSETS
Property, Plant & Equipment $5.894M $7.611M $7.611M
YoY Change 22.5% 65.88% 9.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $293.7K $268.2K $268.2K
YoY Change 9.53% 0.0% 0.0%
Total Long-Term Assets $8.033M $7.879M $7.879M
YoY Change 10.51% 9.33% 9.33%
TOTAL ASSETS
Total Short-Term Assets $41.41M $50.86M $50.86M
Total Long-Term Assets $8.033M $7.879M $7.879M
Total Assets $49.44M $58.73M $58.73M
YoY Change -8.2% 17.25% 17.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.249M $6.250M $6.250M
YoY Change 15.17% 26.94% 26.94%
Accrued Expenses $771.5K $749.1K $749.1K
YoY Change 11.22% 9.83% 9.83%
Deferred Revenue $19.36M $24.27M
YoY Change -37.56% 34.98%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.38M $31.27M $31.27M
YoY Change -28.95% 32.57% 32.57%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M $3.376M $3.376M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities $1.249M $1.487M $1.487M
YoY Change -82.52% -86.9% -86.9%
Total Long-Term Liabilities $4.626M $4.863M $4.863M
YoY Change -56.05% -66.97% -66.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.38M $31.27M $31.27M
Total Long-Term Liabilities $4.626M $4.863M $4.863M
Total Liabilities $31.01M $36.13M $36.13M
YoY Change -34.93% -5.68% -5.68%
SHAREHOLDERS EQUITY
Retained Earnings -$169.2M -$159.4M
YoY Change 16.79% 16.26%
Common Stock $187.3M $181.7M
YoY Change 24.07% 22.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.43M $22.60M $22.60M
YoY Change
Total Liabilities & Shareholders Equity $49.44M $58.73M $58.73M
YoY Change -8.2% 17.25% 17.25%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$9.794M -$762.1K -$22.29M
YoY Change 26.08% -90.13% -23.2%
Depreciation, Depletion And Amortization $331.4K $307.6K $1.069M
YoY Change 44.03% 60.55% 100.49%
Cash From Operating Activities -$1.268M -$11.59M -$25.60M
YoY Change -130.13% 67.98% -620.61%
INVESTING ACTIVITIES
Capital Expenditures $608.6K $729.2K $2.048M
YoY Change 75.04% -40.35% 2.36%
Acquisitions
YoY Change
Other Investing Activities -$8.838M -$5.133M $7.156M
YoY Change 220.37% -180.66% -122.56%
Cash From Investing Activities -$9.502M -$5.863M $5.108M
YoY Change 195.86% -214.01% -114.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.58M
YoY Change 432.52%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.290M 23.17M 25.58M
YoY Change 58699.59% 685.44% 424.84%
NET CHANGE
Cash From Operating Activities -1.268M -11.59M -25.60M
Cash From Investing Activities -9.502M -5.863M 5.108M
Cash From Financing Activities 2.290M 23.17M 25.58M
Net Change In Cash -8.480M 5.710M 5.092M
YoY Change -946.09% 380.01% -120.14%
FREE CASH FLOW
Cash From Operating Activities -$1.268M -$11.59M -$25.60M
Capital Expenditures $608.6K $729.2K $2.048M
Free Cash Flow -$1.877M -$12.32M -$27.64M
YoY Change -148.6% 51.68% -1047.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26778360
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24552688
CY2023 capr Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
0.00
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001133869
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31148320
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25241402
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31148320
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-34058
CY2023 dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2023 dei City Area Code
CityAreaCode
858
CY2023 dei Local Phone Number
LocalPhoneNumber
727-1755
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
CAPR
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
119715277
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31399667
CY2023 dei Auditor Firm
AuditorFirmId
468
CY2023 dei Auditor Name
AuditorName
Rose, Snyder & Jacobs LLP
CY2023 dei Auditor Location
AuditorLocation
Encino, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14694857
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9603242
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
24792846
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
31818020
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
10371993
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
995776
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
919892
CY2023Q4 us-gaap Assets Current
AssetsCurrent
50855472
CY2022Q4 us-gaap Assets Current
AssetsCurrent
42888734
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5560641
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2050042
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2349974
CY2023Q4 us-gaap Other Assets
OtherAssets
268172
CY2022Q4 us-gaap Other Assets
OtherAssets
268172
CY2023Q4 us-gaap Assets
Assets
58734327
CY2022Q4 us-gaap Assets
Assets
50094910
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6222762
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4834683
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
27479
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
89234
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
749112
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
682039
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
24270465
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17980599
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31269818
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23586555
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1486783
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1878070
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9467932
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4863042
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14722261
CY2023Q4 us-gaap Liabilities
Liabilities
36132860
CY2022Q4 us-gaap Liabilities
Liabilities
38308816
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31148320
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25241402
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
31148
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25241
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
181701859
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
148735420
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
235813
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
105244
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159367353
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137079811
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22601467
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58734327
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50094910
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
25178066
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2551469
CY2023 us-gaap Revenues
Revenues
25178066
CY2022 us-gaap Revenues
Revenues
2551469
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36448039
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21816949
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12807886
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10431903
CY2023 us-gaap Operating Expenses
OperatingExpenses
49255925
CY2022 us-gaap Operating Expenses
OperatingExpenses
32248852
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-24077859
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-29697383
CY2023 us-gaap Other Income
OtherIncome
67657
CY2022 us-gaap Other Income
OtherIncome
190582
CY2023 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1728701
CY2022 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
521535
CY2023 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-6041
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-34266
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1790317
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
677851
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22287542
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29019532
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
130569
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
105244
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22156973
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28914288
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26778360
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24552688
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4803534
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4458578
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70304
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
105244
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29019532
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25515349
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7392396
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64601
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
130569
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22287542
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22601467
CY2023 us-gaap Profit Loss
ProfitLoss
-22287542
CY2022 us-gaap Profit Loss
ProfitLoss
-29019532
CY2023 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-6041
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-34266
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1068882
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
533131
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
7392396
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4458578
CY2023 capr Noncash Lease Expenses
NoncashLeaseExpenses
-24282
CY2022 capr Noncash Lease Expenses
NoncashLeaseExpenses
161740
CY2023 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
9824413
CY2022 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
155830
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
75884
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-240045
CY2023 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0
CY2022 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-7550
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1388078
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1718312
CY2023 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-61755
CY2022 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-510154
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3178066
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
27448531
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25596545
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4916637
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
97441506
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
114218737
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
104597249
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
82505961
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1311660
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000243
CY2023 capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
735873
CY2022 capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
1359488
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5108210
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35072507
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25515349
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4803534
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
64601
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
70304
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25579950
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4873838
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5091615
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-25282032
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9603242
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34885274
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14694857
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9603242
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</span></p>
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
39500000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
41400000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12000000.0
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2023 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191463
CY2023Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
366551
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
CY2023 us-gaap Depreciation
Depreciation
1068882
CY2022 us-gaap Depreciation
Depreciation
533131
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7766696
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5769655
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2206055
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1181625
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5560641
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 capr Grant Income
GrantIncome
0
CY2023 capr Grant Income
GrantIncome
0
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
50700000
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36400000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21800000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22200000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28900000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
130569
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
105244
CY2023 capr Commission Rate On Sale Price Per Share
CommissionRateOnSalePricePerShare
0.030
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2976154
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31148320
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2021Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2022 capr Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
0
CY2022 capr Weighted Average Exercise Price Granted
WeightedAverageExercisePriceGranted
0
CY2022 capr Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
CY2022 capr Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2023 capr Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
4935621
CY2023 capr Weighted Average Exercise Price Granted
WeightedAverageExercisePriceGranted
5.70
CY2023 capr Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2023Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
5.61
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2023 capr Share Based Compensation Number Of Plans
ShareBasedCompensationNumberOfPlans
5
CY2023Q4 capr Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant
1232318
CY2023 capr Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock
MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
100000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.85
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.04
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.11
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.21
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.045
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7392396
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4458578
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
8227404
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.46
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
4248136
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.88
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13500000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
867854
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
367422
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12493414
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8636326
CY2023Q4 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
3
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
39200000
CY2023Q4 capr Lessee Operating Lease Base Lease Rent Per Month
LesseeOperatingLeaseBaseLeaseRentPerMonth
58409
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
886672
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
910106
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
676908
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2473686
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
237791
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2235895
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
749112
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1486783
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2235895
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M23D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0724
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2100000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2200000
CY2023 capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q4 capr Milestone Payments To Be Made Upon Successful Completion Of Certain Phases
MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases
10000000.0
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
27479
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
89234
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-002861-index-headers.html Edgar Link pending
0001558370-24-002861-index.html Edgar Link pending
0001558370-24-002861.txt Edgar Link pending
0001558370-24-002861-xbrl.zip Edgar Link pending
capr-20231231.xsd Edgar Link pending
capr-20231231x10k.htm Edgar Link pending
capr-20231231x10k005.jpg Edgar Link pending
capr-20231231x10k006.jpg Edgar Link pending
capr-20231231x10k007.jpg Edgar Link pending
capr-20231231xex21d1.htm Edgar Link pending
capr-20231231xex23d1.htm Edgar Link pending
capr-20231231xex31d1.htm Edgar Link pending
capr-20231231xex31d2.htm Edgar Link pending
capr-20231231xex32d1.htm Edgar Link pending
capr-20231231xex32d2.htm Edgar Link pending
capr-20231231x10k_htm.xml Edgar Link completed
capr-20231231xex4d1.htm Edgar Link pending
capr-20231231xex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
capr-20231231_def.xml Edgar Link unprocessable
capr-20231231_lab.xml Edgar Link unprocessable
capr-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20231231_cal.xml Edgar Link unprocessable